CAJ | 학술논문

非小细胞肺癌治疗手段以手术、化疗、放疗和靶向治疗为主.随着靶向治疗研究的进展,发现表皮生长因子受体(EGFR)突变患者接受小分子酪氨酸激酶抑制剂靶向治疗效果佳.进行这类药物治疗前的筛选是个体化治疗的前提,目前以组织标本基因检测为金标准.但是进展期患者的病理诊断很多时候是根据细胞学标本,部分细胞学标本是惟一的标本来源.近年来肺癌细胞学标本行EGFR检测已经成为一种趋势,主要细胞学标本类型包括外周血、胸腔积液及细针穿刺标本.本文旨在对目前使用细胞学标本评价非小细胞肺癌EGFR基因状态方面做一个概述.
비소세포폐암치료수단이수술、화료、방료화파향치료위주.수착파향치료연구적진전,발현표피생장인자수체(EGFR)돌변환자접수소분자락안산격매억제제파향치료효과가.진행저류약물치료전적사선시개체화치료적전제,목전이조직표본기인검측위금표준.단시진전기환자적병리진단흔다시후시근거세포학표본,부분세포학표본시유일적표본래원.근년래폐암세포학표본행EGFR검측이경성위일충추세,주요세포학표본류형포괄외주혈、흉강적액급세침천자표본.본문지재대목전사용세포학표본평개비소세포폐암EGFR기인상태방면주일개개술.
The main therapies of non-small cell lung cancer (NSCLC) are surgery,chemotherapy,radiotherapy and targeted therapy.With development of targeted therapy,it is found that tyrosine kinase inhibitor is effective for patients with epidermal growth factor receptor (EGFR) mutations.Screening of such drugs before treatment is a premise of individualized treatment,and genetic testing of tissue samples is currently gold standard.In most cases,the diagnosis of lung cancer is performaed on cytological specimens,therefore,there is a need to obtain a complete and reliable molecular diagnosis on cytological specimens.In recent years,EGFR mutation detection in cytological samples of NSCLC has become a trend,and major cytogenetic specimen types include peripheral blood,pleural effusion and fine needle aspiration.This review aims to present an overview of the current knowledge of the use of cytological specimens for the evaluation of EGFR gene states in NSCLC.